MedTrace Logo

Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients

NCT02251067 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2017-03-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

VPI-2690B low dose

Comparison of different doses of study drug

DRUG

VPI-2690B medium dose

Comparison of different doses of study drug

DRUG

Placebo to match VPI-2690B

DRUG

VPI-2690B high dose

Comparison of different doses of study drug

Sponsors & Collaborators

  • Vascular Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Vascular Pharmaceuticals Inc Clinical Trial · Vascular Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02251067 on ClinicalTrials.gov